Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference
04 oct. 2018 06h05 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option
02 oct. 2018 16h05 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
01 oct. 2018 06h05 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Announces Pricing of Public Offering
27 sept. 2018 21h11 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Announces Proposed Public Offering of American Depositary Shares
25 sept. 2018 16h25 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients
22 sept. 2018 11h57 HE
|
Nightstar Therapeutics
NSR-RPGR data presented at EURETINA 2018 Congress demonstrated proof of concept with durable dose-related improvements seen as early as month 1 across multiple microperimetry analyses Preliminary...
Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors
13 sept. 2018 06h05 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, United Kingdom, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare...
Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
13 août 2018 06h05 HE
|
Nightstar Therapeutics
Regenerative Medicine Advanced Therapy (RMAT) Designation received in June 2018 for NSR-REP1 in Choroideremia Preliminary data from Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected...
Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference
07 août 2018 06h05 HE
|
Nightstar Therapeutics
WALTHAM, Mass. and LONDON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia
14 juin 2018 06h05 HE
|
Nightstar Therapeutics
First gene therapy RMAT designation for an inherited retinal diseaseSTAR Phase 3 registrational trial ongoing and FDA interactions plannedRMAT designation enables closer and more frequent...